Direclidine vs NTX-253
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Muscarinic M4 receptor · full Schizophrenia pipeline
Direclidine
Developed by Neurocrine Biosciences under a licence from Nxera Pharma
NCT05545111 · Phase 2 · completed
The study randomly assigned 210 participants to four NBI-1117568 dose groups or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT06963034 (registry estimate)
Reported efficacy
Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score at Week 6 (Baseline and Week 6): PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline (met)
Result source: NCT05545111
NTX-253
Developed by Neurosterix Pharma Sàrl
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Direclidine | NTX-253 |
|---|---|---|
| PANSS total, change | —Trial running · NCT06963034 | —Not reported |
| CGI-S, change | —Trial running · NCT06963034 | —Not reported |
| PANSS response | —Trial running · NCT06963034 | —Not reported |
| PSP, change | —Trial running · NCT06963034 | —Not reported |
| Relapse (% of patients) | —Trial running · NCT06963034 | —Not reported |
PANSS total, change
- Direclidine
- —Trial running · NCT06963034
- NTX-253
- —Not reported
CGI-S, change
- Direclidine
- —Trial running · NCT06963034
- NTX-253
- —Not reported
PANSS response
- Direclidine
- —Trial running · NCT06963034
- NTX-253
- —Not reported
PSP, change
- Direclidine
- —Trial running · NCT06963034
- NTX-253
- —Not reported
Relapse (% of patients)
- Direclidine
- —Trial running · NCT06963034
- NTX-253
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NTX-253: no structured comparison results are available for Schizophrenia.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Direclidine's landscape · NTX-253's landscape